{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":12,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":12,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"59bc5d409406","filters":{"venue":"PharmaDeals Review"}},"results":[{"id":"W150401912","doi":"10.3833/pdr.v2011i6.1485","title":"Boehringer Ingelheim Licenses Zealand Pharma’s Drug Candidates for Type 2 Diabetes and Obesity","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Milestone; Type 2 diabetes; Payment; Obesity; Quarter (Canadian coin); Business; Diabetes mellitus; Internal medicine; Finance; Endocrinology; Geography","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08240199183654418,"gpt":0.3650932836274937,"spread":0.2826912917909495,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004153655,0.0002471634,0.0006403615,0.00005804425,0.0001283473,0.000008584484,0.00009495801,0.00004943004,0.0008761882],"category_scores_gemma":[0.00007672461,0.0001897257,0.0001130404,0.000127634,0.00008269593,0.0001207175,0.00005822555,0.0001653657,0.000112025],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003671734,"about_ca_system_score_gemma":0.00006172236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000025323,"about_ca_topic_score_gemma":0.000004115886,"domain_scores_codex":[0.9987713,0.0000895239,0.0003142387,0.0003311448,0.0001104037,0.0003834529],"domain_scores_gemma":[0.9991663,0.0001345953,0.0001233482,0.000177313,0.0001171578,0.0002813552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007801456,0.001842387,0.5823645,0.02288611,0.00179304,0.0001381849,0.00171898,8.24894e-8,0.009648404,0.000103451,0.3429261,0.03579867],"study_design_scores_gemma":[0.008326405,0.0007671262,0.09135862,0.006354763,0.008431867,0.000161861,0.0000280749,0.00008441479,0.1758341,0.0003534386,0.7074061,0.0008932407],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.644533,0.3512621,0.000002034334,0.001377181,0.0002324086,0.001470615,0.00003269949,0.00009295723,0.0009970007],"genre_scores_gemma":[0.6315562,0.3558418,0.0005311669,0.01026481,0.0001851231,0.0002131738,0.00006512435,0.00003341663,0.001309184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4910059,"threshold_uncertainty_score":0.9593647,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W131397720","doi":"10.3833/pdr.v2011i5.1473","title":"Mundipharma Gains Commercialisation Rights to Allos Therapeutics’ Folotyn® Outside of North America","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Business","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2517164448078097,"gpt":0.4365977792055006,"spread":0.1848813343976909,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005223905,0.0002592839,0.0008631024,0.0001642097,0.00007643428,0.000007222564,0.000332618,0.00004142466,0.01002016],"category_scores_gemma":[0.00004781692,0.0002052339,0.0002864751,0.0006189278,0.0001239087,0.00009524167,0.00008293985,0.0002889283,0.00057381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009734927,"about_ca_system_score_gemma":0.00009264651,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004592748,"about_ca_topic_score_gemma":0.00004716461,"domain_scores_codex":[0.9975982,0.0003412636,0.0007184636,0.0003371954,0.0005748261,0.0004299953],"domain_scores_gemma":[0.9984167,0.0001138618,0.0002280344,0.0006128134,0.0002824122,0.0003461482],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009334626,0.001297704,0.01722693,0.006394162,0.001077192,0.00009434475,0.003928805,0.000001543442,0.04361036,0.000137208,0.02313981,0.9021585],"study_design_scores_gemma":[0.001400004,0.0005211727,0.0155151,0.001652444,0.000731422,0.00003285662,0.00001551335,0.0000321049,0.02396367,0.00007923141,0.9557472,0.0003092434],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4660684,0.3126324,0.002458244,0.02570357,0.001352227,0.02613301,0.0003779931,0.0007798936,0.1644942],"genre_scores_gemma":[0.7131271,0.2409508,0.00189988,0.04114297,0.0003782184,0.0003931728,0.0001609054,0.0001131314,0.001833746],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9326074,"threshold_uncertainty_score":0.9908848,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W73664796","doi":"10.3833/pdr.v2013i11.1991","title":"Endo Looks to Geographic Expansion and Tax Advantages with US$1.6 B Paladin Buyout","year":2013,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Revenue; Stock (firearms); Business; Corporate tax; Offset (computer science); Irish; Footprint; Order (exchange); Emerging markets; Finance; Geography; Engineering; Tax avoidance; Double taxation; Mechanical engineering","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2162782767136228,"gpt":0.427603316892974,"spread":0.2113250401793512,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005811271,0.0002945968,0.001354647,0.0002817252,0.000162025,0.00010061,0.0002657655,0.00006975024,0.00197758],"category_scores_gemma":[0.0007152125,0.0002915271,0.000108268,0.0002738003,0.00006422383,0.0005926579,0.00007736989,0.0001883499,0.005037363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009967596,"about_ca_system_score_gemma":0.0000490634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001062938,"about_ca_topic_score_gemma":0.00004513246,"domain_scores_codex":[0.9956912,0.0002969378,0.002695257,0.0006964187,0.0001133363,0.000506883],"domain_scores_gemma":[0.9973212,0.0003957367,0.001184457,0.0005303312,0.00008626887,0.0004819652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003626774,0.0003253265,0.5971537,0.03103312,0.0004373637,0.00001395871,0.00176934,0.00005294204,0.0001834917,0.02130342,0.3187132,0.0289779],"study_design_scores_gemma":[0.001425711,0.0002493071,0.1072581,0.005807614,0.00007079429,0.00006071253,0.0001931623,0.0003337473,0.00004513231,0.003098093,0.8803573,0.001100284],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.3946304,0.4954806,0.001260009,0.09700602,0.0003945199,0.006313598,0.0003311297,0.0001543018,0.004429416],"genre_scores_gemma":[0.5481746,0.2917822,0.005259005,0.1508915,0.0004100848,0.00209766,0.00006477004,0.0001175814,0.00120262],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.5616441,"threshold_uncertainty_score":0.9999537,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W49293275","doi":"10.3833/pdr.v2012i2.1678","title":"Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Anesthesia and Neurotoxicity Research","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Xenon; General partnership; Medicine; Medical physics; Business; Engineering ethics; Medical education; Engineering; Physics; Finance; Nuclear physics","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1851774888707091,"gpt":0.4072948621059432,"spread":0.2221173732352341,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001237139,0.0001606261,0.0002717568,0.0000452225,0.0001382022,0.00003931392,0.0001609514,0.0000319703,0.00005472703],"category_scores_gemma":[0.000875253,0.000126801,0.00002235724,0.0003967724,0.0000782741,0.0001318822,0.0001252961,0.0001644858,0.0001155252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001309063,"about_ca_system_score_gemma":0.00002149949,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002034456,"about_ca_topic_score_gemma":2.416168e-7,"domain_scores_codex":[0.9980592,0.0007364269,0.0002367518,0.0002661717,0.0002752832,0.0004261315],"domain_scores_gemma":[0.998569,0.0008536762,0.00005353655,0.0001641486,0.0000444918,0.0003151772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000401624,0.0004425971,0.06730719,0.005335071,0.00002077566,0.00006176931,0.000715649,4.99353e-7,0.358369,0.002656122,0.01760094,0.5474502],"study_design_scores_gemma":[0.0001956786,0.00008428536,0.005362332,0.0006901707,0.00004490845,0.0001575895,0.000006413586,0.00007822588,0.1267841,0.00004219416,0.8662826,0.0002715818],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.5888492,0.3858645,0.001235753,0.01868098,0.0001592398,0.004227924,0.00001847054,0.0001802248,0.0007837197],"genre_scores_gemma":[0.4741928,0.4879168,0.0001536745,0.03746811,0.0000642856,0.00009810601,0.000001266125,0.00002188676,0.00008313482],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8486816,"threshold_uncertainty_score":0.5170793,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2309079920","doi":"10.3833/pdr.v2014i9.2063","title":"Roche to Buy InterMune for US$8.3 B to Gain Pirfenidone for Idiopathic Pulmonary Fibrosis","year":2014,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Pirfenidone; Medicine; Franchise; Idiopathic pulmonary fibrosis; Asthma; Omalizumab; Internal medicine; Business; Business administration; Lung; Immunology","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02739605113640022,"gpt":0.3444773393026677,"spread":0.3170812881662675,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001288011,0.0004479615,0.001279219,0.0001660385,0.0001717151,0.00003932471,0.0003759183,0.0001079682,0.0001724743],"category_scores_gemma":[0.0009365873,0.0003891669,0.0008153907,0.0003842029,0.00003712643,0.0001327331,0.0001479633,0.0001910726,0.0003056581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000147947,"about_ca_system_score_gemma":0.0001031662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002151946,"about_ca_topic_score_gemma":0.000001524184,"domain_scores_codex":[0.9970912,0.00013728,0.0009286398,0.0007603089,0.0003454781,0.0007371172],"domain_scores_gemma":[0.9977239,0.000191478,0.0001837669,0.0005999263,0.000400047,0.0009008669],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01583469,0.001177925,0.0002455982,0.1185596,0.0003836842,0.00004886972,0.0002485627,0.00003194293,0.2792911,0.001775755,0.2728425,0.3095597],"study_design_scores_gemma":[0.00136326,0.005840826,0.0003146389,0.03360889,0.001342877,0.0001178875,0.00001747314,0.001524757,0.007356144,0.0002531194,0.9475561,0.0007039633],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.02278106,0.5401024,0.2250993,0.151116,0.003880643,0.04779825,0.002594803,0.001049489,0.005578052],"genre_scores_gemma":[0.8820329,0.0186801,0.008274699,0.07855456,0.003177841,0.006589393,0.0004049305,0.0002294048,0.002056182],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8592518,"threshold_uncertainty_score":0.999856,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W205713971","doi":"10.3833/pdr.v2012i1.1646","title":"Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Diverse Perspectives in Modern Studies","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Divestment; Prestige; Business; Cash; Shareholder; Database transaction; Order (exchange); Hard core; Advertising; Commerce; Finance; Corporate governance","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09439475362979195,"gpt":0.3269323725384922,"spread":0.2325376189087002,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006542355,0.0003379345,0.001167909,0.0001756905,0.0001597738,0.00004354921,0.0004866301,0.00002856197,0.0007007567],"category_scores_gemma":[0.0002483822,0.0003455881,0.0002640249,0.0007211639,0.0001459847,0.0004013824,0.000267852,0.0002081849,0.003990281],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001439819,"about_ca_system_score_gemma":0.00001465755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001910452,"about_ca_topic_score_gemma":0.00002685007,"domain_scores_codex":[0.9978934,0.00002877158,0.000734643,0.0005417818,0.0001008718,0.0007005248],"domain_scores_gemma":[0.9985588,0.00008287239,0.0004263065,0.0005179427,0.00006226591,0.0003518133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003938929,0.0003579523,0.845832,0.001914697,0.0004770676,0.000008130505,0.003287181,0.00002866784,0.00001591514,0.006332452,0.1030151,0.03869152],"study_design_scores_gemma":[0.0005218687,0.00007472505,0.2768206,0.0003974665,0.00009416087,0.000007842906,0.00005872881,0.00005322314,0.00002557737,0.0002577787,0.7210336,0.0006544138],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1798206,0.6814271,0.002324677,0.005810019,0.00169869,0.002548632,0.0009019874,0.0002405473,0.1252278],"genre_scores_gemma":[0.8025231,0.1898998,0.0007874566,0.004919774,0.0004566776,0.0001920081,0.00001755905,0.00005009006,0.001153525],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.6227025,"threshold_uncertainty_score":0.9998996,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W202721108","doi":"10.3833/pdr.v2011i8.1518","title":"Bayer Licenses Regional Rights to Trius Therapeutics’ Phase III Antibiotic for Serious Gram-Positive Infections","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"China; Latin Americans; Medicine; International trade; Political science; Business; Law","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2007572896715127,"gpt":0.3865174937509864,"spread":0.1857602040794737,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005437165,0.0002945887,0.0008335509,0.0002003308,0.0002247289,0.00004915567,0.0003038054,0.00007051911,0.001135055],"category_scores_gemma":[0.00003866891,0.0003009978,0.0003727443,0.0003244164,0.00006486375,0.0002267457,0.00005327235,0.0001876821,0.001388591],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001016974,"about_ca_system_score_gemma":0.00003599252,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001928397,"about_ca_topic_score_gemma":0.0000153957,"domain_scores_codex":[0.9979123,0.00003958862,0.0009631228,0.0005301001,0.00003269618,0.0005221412],"domain_scores_gemma":[0.9987439,0.0001286626,0.0003685088,0.000333563,0.00007806227,0.0003473219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000793168,0.005381387,0.001104704,0.003678282,0.002331241,0.00003615201,0.002685558,0.00001571523,0.0006814833,0.7699059,0.1213518,0.09203458],"study_design_scores_gemma":[0.002414549,0.0002743804,0.0002564959,0.0002901288,0.0001421961,0.00003191565,0.000002752456,0.0002660568,0.001192837,0.01394618,0.9807003,0.0004821804],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.132211,0.6007482,0.01541349,0.04579854,0.004842608,0.02052566,0.006681586,0.0006921367,0.1730868],"genre_scores_gemma":[0.7765279,0.1392045,0.00111921,0.08106887,0.000572882,0.0004215658,0.00009892743,0.0000953721,0.0008907907],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8593485,"threshold_uncertainty_score":0.9999442,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2314904138","doi":"10.3833/pdr.v2011i9.1548","title":"PerkinElmer Agrees to Acquire Caliper Life Sciences for US$600 M","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Calipers; Portfolio; Cash; Business; Database transaction; Quarter (Canadian coin); Marketing; Computer science; Finance; Engineering; Mechanical engineering","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3463556383388496,"gpt":0.4810681235141742,"spread":0.1347124851753246,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002007663,0.0001972828,0.00062054,0.0001672277,0.0001818247,0.00001126691,0.0004083235,0.0000402285,0.003057636],"category_scores_gemma":[0.00125732,0.0001232919,0.0001788279,0.0007976042,0.000339276,0.0001512293,0.00007852853,0.0001304404,0.0004043355],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003308968,"about_ca_system_score_gemma":0.000323689,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008667658,"about_ca_topic_score_gemma":0.000003786381,"domain_scores_codex":[0.9976439,0.0000666769,0.0004370502,0.0004899668,0.0007329384,0.0006294704],"domain_scores_gemma":[0.9983358,0.0001033852,0.00008098537,0.0002780407,0.0002608084,0.0009409694],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003427999,0.0005785042,0.046533,0.01632329,0.0001592169,0.0000728103,0.00238156,7.300235e-7,0.01365515,0.0008212349,0.7584959,0.1606358],"study_design_scores_gemma":[0.001705571,0.001108459,0.01904958,0.006221439,0.0003531969,0.0001028348,0.0001390894,0.00006693447,0.004636608,0.00004684122,0.9662656,0.0003038172],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.2400097,0.624456,0.0006848218,0.05625952,0.00118034,0.01082252,0.00005146441,0.000298637,0.06623698],"genre_scores_gemma":[0.4896606,0.2840993,0.004403931,0.213039,0.001788963,0.0009364827,0.00001802103,0.00006075633,0.005992944],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.3403568,"threshold_uncertainty_score":0.9978537,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W128615782","doi":"10.3833/pdr.v2012i3.1692","title":"Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Dupuytren's Contracture and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Political science; Medicine; Management; Family medicine; Economics","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06126565779868655,"gpt":0.3962955412368063,"spread":0.3350298834381197,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000231161,0.0002355905,0.0006076353,0.00007696345,0.0000407678,0.000008577876,0.00007281642,0.00004178323,0.0009267722],"category_scores_gemma":[0.00004250035,0.0001690769,0.00006267861,0.0002303347,0.00001366425,0.0001678697,0.00002976614,0.0001788113,0.0002701384],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003199241,"about_ca_system_score_gemma":0.0001544251,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.2453186,"about_ca_topic_score_gemma":0.2033988,"domain_scores_codex":[0.9985411,0.0000777099,0.0003823247,0.0002406963,0.0002655651,0.0004926573],"domain_scores_gemma":[0.9989688,0.00005772731,0.00007906989,0.0002405293,0.00003776892,0.0006161112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002399789,0.001029924,0.4441317,0.006633951,0.0004562422,0.001293282,0.0005337812,0.000001508462,0.001906889,0.0003857923,0.2858062,0.2575807],"study_design_scores_gemma":[0.001383525,0.00005611882,0.2365806,0.002932393,0.0004371091,0.0001792737,0.000005244939,0.000001865061,0.002935375,0.00002189267,0.7552236,0.0002429498],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7644293,0.2129067,0.000006428249,0.01395368,0.0004661814,0.00230064,0.00005321454,0.00004036606,0.005843522],"genre_scores_gemma":[0.9643239,0.02155538,0.00009664517,0.0121417,0.0001420716,0.00007316459,0.00004121957,0.00001580147,0.001610085],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4694174,"threshold_uncertainty_score":0.9999865,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2285884689","doi":"10.3833/pdr.v2012i11.1832","title":"Pfizer Forays into ADHD Market by Exercising Option to Acquire NextWave Pharmaceuticals","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Methylphenidate; Attention deficit hyperactivity disorder; Quarter (Canadian coin); Business; Medicine; Psychiatry","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1161500219915705,"gpt":0.458131856071382,"spread":0.3419818340798115,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001642705,0.0003553497,0.0008612123,0.0001115694,0.0001271225,0.0000361485,0.0001564303,0.00009739865,0.008712189],"category_scores_gemma":[0.0005070096,0.0003139498,0.0002820487,0.000539039,0.00004818972,0.0007066487,0.000121921,0.0003308375,0.002360875],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001716695,"about_ca_system_score_gemma":0.00004430633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001080912,"about_ca_topic_score_gemma":2.250334e-7,"domain_scores_codex":[0.9972934,0.0003336532,0.000677789,0.0004212127,0.000572984,0.0007009307],"domain_scores_gemma":[0.9982268,0.0001778194,0.0001876836,0.0004486899,0.0001730667,0.0007859755],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001945687,0.0008873086,0.003013609,0.008559803,0.0001783327,0.00001436886,0.0003988523,0.000001153546,0.05043336,0.00007144491,0.4856866,0.4505606],"study_design_scores_gemma":[0.001196999,0.0000512451,0.000555321,0.004317391,0.001005439,0.0001539978,0.0001551445,0.0001465958,0.002628904,0.00002708562,0.9893203,0.0004415946],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.08286016,0.8485997,0.01219871,0.0379345,0.0009535351,0.005700938,0.00005142848,0.0004055433,0.01129551],"genre_scores_gemma":[0.7893259,0.1651359,0.003105648,0.03717068,0.0007462271,0.0004469115,0.0001367635,0.0001371231,0.003794861],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.7064657,"threshold_uncertainty_score":0.9999313,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W9436761","doi":"10.3833/pdr.v2011i9.1531","title":"Sanofi’s Aventis Pharma Subsidiary to Acquire Nutraceuticals Business of India’s Universal Medicare","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Business; Nutraceutical; Portfolio; Quarter (Canadian coin); Marketing; Finance; Medicine","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1334269315679914,"gpt":0.3308779048758859,"spread":0.1974509733078945,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001083525,0.0003144762,0.001157709,0.0002825385,0.00006586849,0.00001882826,0.0007208507,0.0001127954,0.01260316],"category_scores_gemma":[0.0002007854,0.0003504223,0.0002929117,0.000762057,0.0001365736,0.0003339135,0.0002095992,0.0002271383,0.002541797],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001025818,"about_ca_system_score_gemma":0.00008258168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001201059,"about_ca_topic_score_gemma":0.000002542211,"domain_scores_codex":[0.9973291,0.00006888768,0.001390057,0.0005488427,0.00007806792,0.0005850063],"domain_scores_gemma":[0.9981944,0.00008175366,0.0005428947,0.0004805626,0.0001025991,0.0005978125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000408995,0.002510083,0.06552561,0.0288814,0.001852802,0.0002733424,0.004251315,0.00001294176,0.001111723,0.5607494,0.2152981,0.1191243],"study_design_scores_gemma":[0.001257582,0.00006690047,0.01921851,0.001318685,0.0001630494,0.00002809988,0.00002797008,0.00008760898,0.00294265,0.005657011,0.9684638,0.0007681038],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.06785249,0.6190192,0.001302643,0.02153996,0.002489903,0.003654482,0.003036189,0.0002306779,0.2808744],"genre_scores_gemma":[0.7136658,0.2646221,0.0005725984,0.02041979,0.0002478893,0.0000907452,0.00004753169,0.00006986431,0.000263618],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.7531657,"threshold_uncertainty_score":0.9998948,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1578951455","doi":"10.3833/pdr.v2013i4.1921","title":"Lundbeck and Otsuka Expand Alliance with Deal for Late-Stage Alzheimer’s Disease Programme","year":2013,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Alliance; Product (mathematics); Disease; Political science; Business; Medicine; Internal medicine","authors":[{"name":"Heather Cartwright","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1399369246955383,"gpt":0.4159867448974022,"spread":0.276049820201864,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006611079,0.0002206787,0.0005515865,0.00004482204,0.0001062004,0.00003913059,0.0001521239,0.00002963239,0.0007392197],"category_scores_gemma":[0.0001773611,0.000133795,0.00008444503,0.0002798072,0.0002589901,0.0002158756,0.00004027869,0.000171139,0.000130037],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002455317,"about_ca_system_score_gemma":0.0002328301,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006668106,"about_ca_topic_score_gemma":0.000004948575,"domain_scores_codex":[0.9980415,0.00005121857,0.0003297884,0.0004454013,0.0004864063,0.0006456787],"domain_scores_gemma":[0.9980068,0.0001108731,0.0001063984,0.0003122796,0.0002443305,0.001219352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005534855,0.0005065628,0.03125897,0.03017979,0.0003342048,0.0002031189,0.0002979481,0.00000143537,0.001867346,0.0003074091,0.07619192,0.8582978],"study_design_scores_gemma":[0.004862514,0.0007128756,0.01637125,0.008830935,0.001165562,0.00004751054,0.00006702082,0.0007735189,0.0006141427,0.00006977984,0.9661095,0.0003754623],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.09179043,0.8695039,0.0002385698,0.02588168,0.00009302337,0.01103231,0.00003505423,0.0001296343,0.001295438],"genre_scores_gemma":[0.1778845,0.7729759,0.005531962,0.02829176,0.0006578936,0.005041745,0.0001923692,0.000105748,0.009318195],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8899175,"threshold_uncertainty_score":0.8093938,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}